Abilify (aripiprazol) is a new atypical antipsychotic approved for the treatment of schizophrenia. Unlike other atypical antipsychotic drugs, which exert pure D2-antagonism, aripiprazol has a partially agonistic effect on dopamine D2 receptors.
The clinical effect is equal to other atypical antipsychotics. The cost is in line with other atypical antipsychotics.
Apart from this, aripiprazol has displayed efficacy against manic episodes.
Aripiprazol was marketed July 5, 2004.
Last modified: November 29th 2005